Home » Topics » Disease categories and therapies » Cancer

Cancer
RSS

New phase II trials to evaluate KOS-862 for various cancers

Dec. 11, 2003

Sugen identifies potential surrogate markers for SU-11248 activity

Dec. 11, 2003

Dual-acting estrogen sulfatase inhibitor and SERM presented in San Antonio

Dec. 10, 2003

Avastin submitted for approval in Europe for colorectal cancer

Dec. 10, 2003

Cyclacel acquires rights to CYC-682

Dec. 10, 2003

Enrollment to begin in phase I/II trial of CB-001

Dec. 10, 2003

New site added to international phase II study of Litx

Dec. 9, 2003

Treatment commences in pivotal European phase II trial of clofarabine for ALL

Dec. 9, 2003

Allos completes RSR-13 NDA filing

Dec. 9, 2003

CC-5079 induces NF-B-independent apoptosis of hematopoietic cancer cells

Dec. 9, 2003

Popular Stories

Today's news in brief
BioWorld
BioWorld briefs for March 27, 2026.
ADPD 2026: Three inflection points to target Alzheimer’s disease
BioWorld Science
A new way of understanding Alzheimer’s disease, based on biological inflection points that mark decisive moments in the progression of the disorder, could change...
Emerging therapeutic strategies for Parkinson’s at ADPD 2026
BioWorld
Parkinson’s disease (PD) involves the progressive loss of dopaminergic neurons, particularly in the substantia nigra. This neurodegeneration is linked to the...
Small-molecule TREM2 agonist advances to treat Alzheimer’s
BioWorld Science
Microglia play a central role in the neuroinflammation associated with Alzheimer’s disease (AD). These cells act as the brain’s immune system and respond to...
With improved technologies, biomarkers, failed drugs may come into their own
BioWorld
At BioEurope Spring 2026, pharma representatives and investors shared their thoughts about current and future landscapes of different disease areas, and on how to...